Connor, Clark & Lunn Investment Management Ltd. 4 D Molecular Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 65,354 shares of FDMT stock, worth $292,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,354
Previous 27,323
139.19%
Holding current value
$292,132
Previous $295,000
23.39%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding FDMT
# of Institutions
149Shares Held
57.9MCall Options Held
137KPut Options Held
111K-
Bvf Inc San Francisco, CA7.38MShares$33 Million2.54% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.1MShares$22.8 Million0.77% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$21.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$19.7 Million4.93% of portfolio
-
Goldman Sachs Group Inc New York, NY4.27MShares$19.1 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $145M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...